Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 2/20 | 0.69 |
| ▸ | ECE1 | P42892 | 5/20 | 0.67 |
| ▸ | MME | P08473 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | REN | P00797 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 1/20 | 0.61 |
| ▸ | MMP14 | P50281 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12062839 | 1.00 | NMBR (0.69) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL12052816 | 1.00 | NMBR (0.69) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL5380211 | 1.00 | NMBR (0.69) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL12052755 | 1.00 | NMBR (0.69) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL8403999 | 1.00 | NMBR (0.69) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL14595066 | 0.91 | NMBR (0.76) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL29386277 | 0.91 | NMBR (0.76) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL3808330 | 0.91 | NMBR (0.76) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL29401760 | 0.91 | NMBR (0.76) | NMBRECE1MMEMAPTGAA | |
| SCHEMBL1285921 | 0.91 | NMBR (0.76) | NMBRECE1MMEMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657058-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2015-12-10 | — | — | US | disclosed |
| US-8765745-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8735441-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8431571-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8080576-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| WO-2007149512-A2 | PEPTIDE EPOXYKETONES FOR PR0TEAS0ME INHIBITION | PROTEOLIX, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053303-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
| US-20150353601-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
| US-20140080753-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
| US-20130035297-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
| US-20100144649-A1 | COMPOUNDS FOR ENZYME INHIBITION | PSME1, PSMB1, PSME3 | NMBR 4028/4885ECE1 250/4885MME 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.